A new investigational drug known as enzalutamide adds an average of five months to the lives of men with advanced prostate cancer, a new study has found. This is such a significant finding that the trial was stopped early so men receiving a placebo could opt to take enzalutamide. “We found a hormonal drug prolongs the lives of men who have failed traditional hormones as well as chemotherapy,” said lead researcher Dr. Howard Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City.
